| Abstrakt: |
A recent study from the University of Adelaide in Australia has explored the use of a site-specific drug release method for treating oxidative stress disorders. By chemically modifying the NRF2 activator monomethyl fumarate, researchers were able to target oxidative stress sites and reduce systemic side effects in mice, effectively reversing chronic pain. Funded by various organizations including the NIH and Australian Research Council, this research offers promising insights into potential treatments for disorders related to oxidative stress. [Extracted from the article] |
